The RGD peptide agent is proven to significantly reduce kidney impairment symptoms, such as albumin excretion and mesangial expansion, in people with type 2 diabetes and mice with Ins2Akita/+type 1 diabetes. Here, ALB is linked to type 2 diabetes mellitus.